ArticleNPJ vaccines2026
Population-level impact of quadrivalent HPV vaccination in Brazil: a repeated cross-sectional study.
Article in NPJ vaccines, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
0 citing papers in PubMed.
No citing paper in PubMed yet.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
10 authors.
Funding
Abstract
Human papillomavirus vaccination is central to cervical cancer elimination, yet population-level evidence from middle-income countries remains limited. We evaluated the impact of quadrivalent HPV vaccination in Brazil using data from two repeated population-based cross-sectional surveys conducted in 2016-2017 and 2020-2023 among sexually active individuals aged 16-25 years. Genital samples were tested for HPV genotyping and survey-weighted Poisson-regression models adjusted for sociodemographic and behavioral factors were used to compare prevalences between periods. Among 11,794 women and 4932 men, the prevalence of vaccine-type HPV declined from 15.64% (14.23-17.17) to 5.92% (5.23-6.70) among women and 13.81% (11.15-16.99) to 10.39% (8.35-12.85) among men. Adjusted analyses showed an 81% reduction among vaccinated women (PR0.19; 0.14-0.27) and a 33% reduction among unvaccinated women (PR0.67; 0.55-0.81), suggesting both direct and indirect effects. Reductions were significant only among women aged 16-23, the group with higher coverage. Among men, lower prevalence of vaccine-type HPV was observed only among vaccinated individuals (PR0.39; 0.18-0.86). The overall HPV prevalence increased modestly between the two surveys. No differences in prevalence reduction were observed according to the number of vaccine doses. These findings demonstrated the impact of HPV vaccination in Brazil and highlight the importance of maintaining high vaccination coverage and continued surveillance.
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.